Matthew Winkler
Director/Board Member at AKOYA BIOSCIENCES, INC.
Net worth: 4 M $ as of 30/04/2024
Matthew Winkler active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AKOYA BIOSCIENCES, INC. | Director/Board Member | 01/07/2017 | - |
| Independent Dir/Board Member | 01/07/2017 | - | |
| The Breakthrough Institute | Director/Board Member | 01/01/2017 | - |
| Revive & Restore | Director/Board Member | 01/01/2017 | - |
| Genetic Literacy Project | Director/Board Member | 01/01/2017 | - |
Career history of Matthew Winkler
Former positions of Matthew Winkler
| Companies | Position | Start | End |
|---|---|---|---|
Ambion, Inc.
 Ambion, Inc. Pharmaceuticals: MajorHealth Technology Ambion, Inc. develops and supplies RNA based life science research and molecular biology products. It specializes in the development of products for stabilizing, synthesizing, handling, isolating, storing, detecting and measuring RNA. The company was founded in November 1988 and is headquartered in Austin, TX | Chief Executive Officer | 01/01/1988 | 01/03/2016 |
| Founder | 19/04/2010 | 01/03/2016 | |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Director/Board Member | 07/07/2010 | 01/03/2016 |
| The University of Texas at Austin | Corporate Officer/Principal | 01/01/1983 | 01/01/1991 |
Mirna Therapeutics, Inc.
 Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Director/Board Member | 01/12/2007 | - |
| Founder | 01/01/2007 | - | |
| Independent Dir/Board Member | 01/12/2007 | - | |
Asuragen, Inc.
 Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Chairman | 15/04/2010 | - |
| Founder | 01/03/2006 | - | |
| President | 01/03/2006 | 11/06/2013 |
Training of Matthew Winkler
| University of California, Berkeley | Doctorate Degree |
Statistics
International
| United States | 11 |
Operational
| Director/Board Member | 6 |
| Founder | 3 |
| Independent Dir/Board Member | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| AKOYA BIOSCIENCES, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Health Technology |
Ambion, Inc.
Ambion, Inc. Pharmaceuticals: MajorHealth Technology Ambion, Inc. develops and supplies RNA based life science research and molecular biology products. It specializes in the development of products for stabilizing, synthesizing, handling, isolating, storing, detecting and measuring RNA. The company was founded in November 1988 and is headquartered in Austin, TX | Health Technology |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Second Genome, Inc. develops microbiome-based therapeutic products. It offers phyclochip community, 16S sequencing community analysis, whole metagenomic profiling, nucleic acid isolation, inferred function and custom informatics services. The company was founded in 2009 by Corey S. Goodman, Janet A. Warrington, Todd Z. DeSantis, John Hulls and Gary Andersen and is headquartered in South San Francisco, CA. | Health Technology |
| The Breakthrough Institute | |
| Revive & Restore | |
| Genetic Literacy Project | |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |
- Stock Market
- Insiders
- Matthew Winkler
- Experience
